(MYNZ) Wednesday Morning Update: Key Details On Your Nasdaq Profile
MYNZ needs top spot on your watch-list again today. Here's why.
Tuesday, MYNZ closed green, up approximately 7% from Monday's close.
But why is that special? It's special because the Dow and Nasdaq took a beating yesterday.
On top of that, it has some game-changing news that has only been out for just over 24 hours. As it continues to circulate, MYNZ could be in for a ton of added exposure.
Check out the news here: Mainz Biomed Announces IRB Approval and Initiation of US Pivotal FDA Clinical Study
Furthermore, MYNZ closed above several lines of potential support including its:
- 5-Day Simple Moving Average (SMA)
- 20-Day SMA
- 50-Day SMA
- 5-Day Exponential Moving Average (EMA)
- 13-Day EMA
If potential support keeps growing at these levels, it could act as the building blocks for a continued vertical run near term.
Read my initial MYNZ report below and get this Nasdaq past champ back on radar quickly.
Tuesday's opening bell is nearly here. Here's what you need to know.
I've been tracking a specific Nasdaq past champ that requires full attention ASAP.
In fact, this isn't just a 1X past champ, it's a 2X past champ.
When I delivered this idea to your inboxes originally, it went absolutely bonkers.
Running an insane 200+% (approx.) in the short term, it turned into a stunning multi-dollar mover.
With its breakout potential starting to grow again, I brought it back to attention only to watch it pop another 30+% in a very little period of time.
Now, with several key potential catalysts including a low float, huge revenue news, a recent corporate update, and a November press release regarding the U.S. extension of a prefeasibility study, it needs to own the top spot on your watch-list immediately.
Right now, there is only one profile to be watching closely at Tuesday, December 6th's opening bell:
*Mainz Biomed B.V. (MYNZ)*
Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company's flagship product is ColoAlert, an accurate, non-invasive, and easy-to-use early detection diagnostic test for colorectal cancer.
And right now, 5 potential catalysts could provide this profile with a breakout spark near term. Here's what to know:
No. 1 - Low Float Volatility Could Be On Display Daily
No. 2 - Two Different Analysts Provide An Average Price Target Of $20
No. 3 - Company Announces eAArly DETECT, U.S. Extension Of Key Prefeasibility Study
No. 4 - Q3 Update Paints The Picture Of A Company Moving In The Right Direction
No. 5 - Key Company Highlights (Including Revenue Growth) Provide A Bullish Future Outlook
But more on those in a second...
About MYNZ: Early Identification Of Cancer Saves Lives
Mainz BioMed – founded in Mainz, Germany and aiming to become a leading provider of easy-to-use diagnostic solutions for patients everywhere.
Developing market-ready molecular in-vitro diagnostics tests since 2010.
Their goal is to place effective solutions where they need to be… In your hands.
A Blockbuster Early Detection Test for Colorectal Cancer
Significant Impact: Colorectal cancer is the 2nd most lethal cancer in the US, but also highly preventable; with early detection providing 5-year survival rates above 90%.
Revenue Generating: ColoAlert is CE-IVD marked and is approved for sale in Europe. European sales will provide near-term revenue potential, while we prepare our entry into the US market. Process launched in 1Q2022.
U.S. Markets: We have begun the FDA process. Recent FDA guidance recommends colorectal cancer screening for everyone over the age of 45, which translates to market potential of over 52Mn tests per year.
Ease of Use: Non-invasive test, which can be taken at home, with rapid response of 92% specificity and 85% sensitivity (which is expected to be increased for the FDA product). Designed to be easier to administer than Exact Science’s ColoGuard, more accurate than FIT, and much less invasive than a colonoscopy.
Experienced Management: Seasoned and experienced management, board & advisors with particular skill sets in commercializing and monetizing medical diagnostics at some of the largest medical companies in the world.
Attractive Valuation: They believe their current valuation holds tremendous upside.